In Vitro Activities of Rabeprazole, a Novel Proton Pump Inhibitor, and Its Thioether Derivative Alone and in Combination with Other Antimicrobials against Recent Clinical Isolates of Helicobacter pylori

AUTOR(ES)

Kawakami, Yoshiyuki

FONTE

American Society for Microbiology

RESUMO

The MICs of rabeprazole sodium (RPZ), a newly developed benzimidazole proton pump inhibitor (PPI), against 133 clinical Helicobacter pylori strains revealed a higher degree of activity than the another two PPIs, lansoprazole and omeprazole. Time-kill curve assays of RPZ, when combined with amoxicillin, clarithromycin, or metronidazole, disclosed that synergistic effects were demonstrated in combination with each antibiotic examined. Moreover, no apparent antagonistic effect appeared among all of the strains tested.

Documentos Relacionados

• A Novel Action of the Proton Pump Inhibitor Rabeprazole and Its Thioether Derivative against the Motility of Helicobacter pylori
• Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori.
• Oxygen concentration influences proton pump inhibitor activity against Helicobacter pylori in vitro.
• In Vitro Activities of Linezolid Alone and in Combination with Amoxicillin, Clarithromycin, and Metronidazole against Helicobacter pylori
• In Vitro Activities of a New Ketolide, ABT-773, Alone and in Combination with Amoxicillin, Metronidazole, or Tetracycline against Helicobacter pylori